Mpox, Smallpox Mpox, Smallpox
Conditions
Interventions
Tecovirimat Arm (Treatment arm): Tecovirimat will be administered as follows:
Body weight
For those whose body weight is 13 kg or more - less than 25 kg: 200 mg should be taken orally every 12 hours a
Sponsors
Morioka Shinichiro
Ohmagari Norio
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who can provide written consent for participation in the study. 2) Male or female patients whose weight is 13kg or more. 3)Patients who are diagnosed with mpox or smallpox.However, smallpox is diagnosed when the pathogen is detected in a blister, pustule, crust,pharyngeal swab, or blood specimen, etc., and Mpox is diagnosed when the pathogen is detected in a skin or mucosal lesion, blister contents, nasopharyngeal swab, pharyngeal swab, anorectal swab, other mucosal swab, blood, urine, or other materials suitable for the test method, by the following methods. The diagnosis is made when pathogens are detected in pharyngeal swab fluid, anorectal swab fluid, other mucous membrane swab fluid, blood, urine, or other materials suitable for the test metho d by the following methods -Direct observation of virus particles by electron microscopy -Detection of pathogens by isolation and identification -Detection of pathogen antigens by fluorescent antibody method -Detection of pathogen genes by PCR method 4)Patients who agree to be hospitalised until the first Tecovirimat course of oral treatment is completed, if oral Tecovirimat is administerd. 5) Patients with severe mpox or mpox with high risk of severe disease All of 1)-3) must be met. As for mpox patients, 4) and 5) also must be met.
Exclusion criteria
Exclusion criteria: 1) Patients who have experienced any anaphylactic reaction to oral Tecovirimat or its ingredients. 2)Patients whom the study doctor considered to be ineligible. Note 1) breast-feeding females will be counseled that tecovirimat has not been studied in breast-feeding women and may opt to cease breast-feedingfor the duration of the treatment and at least 30 days after the last dose of drug and thus be eligible for the treatment arm. Women who choose to continue breast-feeding will not be enrolled in the treatment arm. Note 2) Although reproductive toxicity has not been adequately evaluated in animal studies, no cle ar reproductive toxicity has been demonstrated to date. However, due to the lack of actual experience with administration to pregnant human women, the drug's package insert states that administration of Tecovilimat during pregnancy is not recommended. However, because there are no other candidates for effective treatment against mpox or smallpox, and because mpox can be transmitted transplacental to the fetus, causing miscarriage, premature delivery, or stillbirth, pregnant individuals should be fully aware of the above advantages and disadvantages of tecovirimat administration before they are eligible to participate as a dosing group The pregnant woman must fully understand the advantages and disadvantages of Tecovilimat administration described above to be eligible to participate in the study. Note 3) In the case that a patient in the non-treatment arm wishes to join the treatment arm, the patient will be allowed to do so if the study doctor judges appropriate, after withdrawing the consent and providing another written consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ratio of the patients whose Ct value of PCR testingusing specimens from rash lesions equals or exceeds 40 after 14 days of study inclusion. | — |
Secondary
| Measure | Time frame |
|---|---|
| -Mortality rate 14 and 30 days after the participation of the study. -Viral load in blood, pharyngeal swabs, skin and urine sample 14, 21, 30, 60 and 120 days after the participation of the study. However, when multiple courses of Tecovirimat are administered, virus levels in blood, throat wipes, skin, and urine are not evaluated. -Viral load in semen 60 and 120 days after the participation of the study. -Duration for which the body temperature is 37.5 degrees Celsius or higher after the participation of the study. -Occurrence of adverse events after the participation of the study. -General condition (bedridden, briefly bedridden, or completely bedridden) at study entry, 14 days, and 30 days after entry | — |
Contacts
Public ContactSho Saito
Japan Institute for Health Security (JIHS)
Outcome results
None listed